Savior Lifetec Corporation (4167) Fair Value & Analysis
Healthcare · TW · Market cap 6.2B TWD
Fair value as of: Jun 24, 2026
Analysis
Savior Lifetec Corporation (4167) currently trades at 19.10 TWD, while our model-based Fair Value estimate is 15.71 TWD — implying the stock looks roughly 17.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Savior Lifetec Corporation engages in the research, development, design, manufacture, and sale of carbapenem generics in the Americas, Asia, Taiwan, Europe, and internationally. The company offers injection generics, controlled-release generics, the development of new dosage forms and drugs, and the APIs, excipients, intermediates, and dosage forms. It also provides medicine manufacturer technology and services. In addition, the company sells antibacterial raw materials and injectables. Savior Lifetec Corporation was founded in 1993 and is headquartered in Tainan City, Taiwan.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Savior Lifetec Corporation (4167) undervalued?
What is the fair value of 4167?
What is the quality score of 4167?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.